Predatory journals: what can we do to protect their prey? Read more about Predatory journals: what can we do to protect their prey?
IL-23 inhibition for chronic inflammatory disease. Read more about IL-23 inhibition for chronic inflammatory disease.
Preventing generalised pustular psoriasis. Read more about Preventing generalised pustular psoriasis.
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Read more about Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.
Reducing the risks of nuclear war-the role of health professionals. Read more about Reducing the risks of nuclear war-the role of health professionals.
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial. Read more about Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial.
Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune Deficiency Treatment Consortium. Read more about Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune Deficiency Treatment Consortium.
Transcriptomics aids differentiation of IL-23 overactivity in a patient with atypical skin and joint disease. Read more about Transcriptomics aids differentiation of IL-23 overactivity in a patient with atypical skin and joint disease.
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Read more about Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
The addition of pelvic lymph node treatment to prostate bed salvage radiotherapy - Authors' reply. Read more about The addition of pelvic lymph node treatment to prostate bed salvage radiotherapy - Authors' reply.
